Literature DB >> 21235427

Tumor heterogeneity and strategies to overcome kinase inhibitor resistance in cancer: lessons from melanoma.

Vito W Rebecca, Keiran Sm Smalley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21235427      PMCID： PMC3078022          DOI： 10.1517/13543784.2011.546218

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN： 1354-3784            Impact factor:   6.206


× No keyword cloud information.
  18 in total

1.  Melanoma--an unlikely poster child for personalized cancer therapy.

Authors:  Keiran S M Smalley; Vernon K Sondak
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

2.  BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.

Authors:  Ryan B Corcoran; Dora Dias-Santagata; Kristin Bergethon; A John Iafrate; Jeffrey Settleman; Jeffrey A Engelman
Journal:  Sci Signal       Date:  2010-11-23       Impact factor: 8.192

Review 3.  Mechanisms of drug resistance in kinases.

Authors:  Rina Barouch-Bentov; Karsten Sauer
Journal:  Expert Opin Investig Drugs       Date:  2011-02       Impact factor: 6.206

4.  Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases.

Authors:  Keiran S M Smalley; Nikolas K Haass; Patricia A Brafford; Mercedes Lioni; Keith T Flaherty; Meenhard Herlyn
Journal:  Mol Cancer Ther       Date:  2006-05       Impact factor: 6.261

5.  Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors:  Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

6.  Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells.

Authors:  F M Kaplan; Y Shao; M M Mayberry; A E Aplin
Journal:  Oncogene       Date:  2010-09-06       Impact factor: 9.867

7.  MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.

Authors:  Chen Chen Jiang; Fritz Lai; Rick F Thorne; Fan Yang; Hao Liu; Peter Hersey; Xu Dong Zhang
Journal:  Clin Cancer Res       Date:  2010-11-18       Impact factor: 12.531

8.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.

Authors:  Ramin Nazarian; Hubing Shi; Qi Wang; Xiangju Kong; Richard C Koya; Hane Lee; Zugen Chen; Mi-Kyung Lee; Narsis Attar; Hooman Sazegar; Thinle Chodon; Stanley F Nelson; Grant McArthur; Jeffrey A Sosman; Antoni Ribas; Roger S Lo
Journal:  Nature       Date:  2010-11-24       Impact factor: 49.962

9.  Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma.

Authors:  M Sensi; G Nicolini; C Petti; I Bersani; F Lozupone; A Molla; C Vegetti; D Nonaka; R Mortarini; G Parmiani; S Fais; A Anichini
Journal:  Oncogene       Date:  2006-02-06       Impact factor: 9.867

10.  COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.

Authors:  Cory M Johannessen; Jesse S Boehm; So Young Kim; Sapana R Thomas; Leslie Wardwell; Laura A Johnson; Caroline M Emery; Nicolas Stransky; Alexandria P Cogdill; Jordi Barretina; Giordano Caponigro; Haley Hieronymus; Ryan R Murray; Kourosh Salehi-Ashtiani; David E Hill; Marc Vidal; Jean J Zhao; Xiaoping Yang; Ozan Alkan; Sungjoon Kim; Jennifer L Harris; Christopher J Wilson; Vic E Myer; Peter M Finan; David E Root; Thomas M Roberts; Todd Golub; Keith T Flaherty; Reinhard Dummer; Barbara L Weber; William R Sellers; Robert Schlegel; Jennifer A Wargo; William C Hahn; Levi A Garraway
Journal:  Nature       Date:  2010-11-24       Impact factor: 49.962
View more
  3 in total

1.  Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer.

Authors:  Judith E Unterlass; Arnaud Baslé; Timothy J Blackburn; Julie Tucker; Céline Cano; Martin E M Noble; Nicola J Curtin
Journal:  Oncotarget       Date:  2016-08-22

Review 2.  Dabrafenib and its potential for the treatment of metastatic melanoma.

Authors:  Alexander M Menzies; Georgina V Long; Rajmohan Murali
Journal:  Drug Des Devel Ther       Date:  2012-12-11       Impact factor: 4.162

3.  Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.

Authors:  Jennifer Yang; Matthew A Bill; Gregory S Young; Krista La Perle; Yosef Landesman; Sharon Shacham; Michael Kauffman; William Senapedis; Trinayan Kashyap; Jean-Richard Saint-Martin; Kari Kendra; Gregory B Lesinski
Journal:  PLoS One       Date:  2014-07-24       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.